Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI in connection with the three parallel acquisitions of Installationsgruppen, Ventab and Ventilationsprojekt
Mandate

Vinge advises Axcel VI in connection with the three parallel acquisitions of Installationsgruppen, Ventab and Ventilationsprojekt

October 16, 2020 Employment and Benefits Banking and Finance M&A EU, Competition and Regulatory Commercial Agreements

Vinge has advised Axcel VI in connection with the three parallel acquisitions of Installationsgruppen Partners AB, Ventab Partners AB and Ventilationsprojekt i Sverige AB, which creates a leading installation group within HVAC, sprinkler and building automation.

The newly formed group, by the name Currentum, has a turnover of approximately SEK 900 million with over 300 employees. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted primarily of partner Christina Kokko and associates Karl Klackenberg, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), partner Mikael Ståhl and associate Karl-Gustaw Tobola (Financing), Lisa Hörnqvist (Commercial Agreements), Isak Willborg (Construction), Ebba Svenburg (Employment), Olof Löfvenberg (Real Estate and Environment), Johan Wahlbom (Competition Law), and Viktoria Owetz Leyva (VDR-assistant).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026